About Inari Medical, Inc
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California. Address: 9 Parker, Irvine, CA, United States, 92618
Inari Medical, Inc News and around…
Latest news about Inari Medical, Inc (NARI) common stock and company :
Andrew Hykes, Chief Operating Officer at Inari Medical (NASDAQ:NARI), made a large insider sell on October 19, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Hykes sold 9,000 shares of Inari Medical at prices ranging from $85.47 to $89.16. The total transaction amounted to $789,878. Following the transaction, Hykes still owns 160,827 shares of Inari Medical worth $14,374,829. Inari Medical shares are trading d
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Inari Medical Inc (NARI) was identified as having a larger market cap than the smaller end of the S&P 500, for example Discovery Inc (DISCA), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..
Some COVID-19 stocks are pretty famous. But other lesser-known names are flying high, too.
IRVINE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced planned enrollment of the PEERLESS trial. PEERLESS is a new randomized controlled trial (RCT) comparing the clinical outcomes of patients with intermediate-high risk pulmonary embolism (“PE”) treated with the FlowTriever System versus catheter-directed thromboly
In this article you are going to find out whether hedge funds think Inari Medical, Inc. (NASDAQ:NARI) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
William Hoffman, President And CEO at Inari Medical (NASDAQ:NARI), made a large insider sell on October 7, according to a new SEC ...
Every investor in Inari Medical, Inc. ( NASDAQ:NARI ) should be aware of the most powerful shareholder groups...
Investors continue to be optimistic about Inari Medical (NARI) owing to its focus on understanding the venous system and its commitment toward patient care.
IRVINE, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Mr. Dana G. Mead, Jr. to its board of directors. Mr. Mead will serve as a member of the Compensation Committee of the board. “We are pleased to welcome Dana as a new independent director to our board. Mr. Mead’s decades of executive ope
Thomas Tu, Chief Medical Officer at Inari Medical (NASDAQ:NARI), made a large buy and sell of company shares on September 27, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Thomas Tu exercised options to purchase 5,000 Inari Medical shares for $0 on September 27. They then sold their shares on the same day in the open market. They sold at prices ranging from $82.12 to $83.68 to raise a total of $414,311 from the stock sa
When investing in big and growing industries, a group of stocks can be the best way to go.
Pulled from Benzinga Pro data, Inari Medical (NASDAQ:NARI) showed a loss in earnings since Q1, totaling $4.11 million. Sales, on the ...
It doesn't take a lot of upfront cash to add one of these stocks to your portfolio.
Donald B Milder, at Inari Medical (NASDAQ:NARI), made a large insider sell on September 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Milder sold 7,000 shares of Inari Medical at a price of $81.1 per share. The total transaction amounted to $567,167. Milder still owns a total of 4,787,817 of Inari Medical worth, $366,651,025. Inari Medical shares are trading down 3.72% at $76.58 at the time of this writing
All three of these growth stocks are poised to put up big gains once more investors land on the same page as investment bank analysts who follow them.
Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.
William Hoffman, President And CEO at Inari Medical (NASDAQ:NARI), made a large insider sell on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Hoffman sold 30,000 shares of Inari Medical at a price of $81.41 per share. The total transaction amounted to $2,447,099. Following the transaction, Hoffman still owns 700,831 shares of Inari Medical worth $57,285,925. Inari Medical shares were down at $81.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Total US Market AlphaDEX ETF (TUSA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $54.18 per unit.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
There's a stock on this list analysts think can climb by around 47%, as soon as more investors come around to their way of seeing things.
Even the median estimate would be a 70% gain.
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 11.43% was delivered by the fund’s institutional shares for the Q2 of 2021, outperforming both its S&P 500 and Russell 3000 Health Care benchmarks that delivered […]
The stock price is collapsing as a result.
Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last ...
Inari Medical Inc's(NASDAQ: NARI)Q2 revenue was $63.5 million, more than doubled from $25.4 million in Q2 FY20, ...
The Dow and S&P 500 both nabbed intraday record highs today, the Nasdaq slipped lower.
Gainers Dyadic International (NASDAQ:DYAI) stock increased by 28.96% to $4.63 during Wednesday's regular session. ...